ArticleBasic & clinical pharmacology & toxicology2026
Patients' Perspectives on Antidepressant Discontinuation and the Pharmacists' Role.
Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antidepressant (AD) discontinuation care asks for tailored support and alignment with patients' expectations, needs and wishes. However, studies on patients' experiences and perspectives regarding the contribution of the pharmacist to AD discontinuation care are limited. The aim was to gain a deeper understanding of patients' perspectives regarding guidance during AD discontinuation and patients' views on the contribution of the pharmacist. A qualitative, explorative study was conducted with 15 semistructured face-to-face and video call interviews. Inclusion criteria were age ≥ 18 years and current or past use of ADs. The audiotapes were transcribed verbatim, coded and analysed by two researchers. The following four themes were identified: (1) experiences with ad use and discontinuation, (2) attitudes and behaviour towards AD discontinuation, (3) expectations and perceptions towards AD discontinuation and (4) needs regarding AD discontinuation. False beliefs about ADs and past negative experiences with AD discontinuation shape beliefs of patients that amount to a reluctance to discontinue ADs. The most urgent needs of patients were timely receiving guidance, including clear and relevant information from accessible, knowledgeable and trustable healthcare providers (HCPs). Pharmacists' easy accessibility, pharmacotherapeutic knowledge, expertise and capabilities should be put to use, as they may help meeting patients' needs on AD discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.